China’s greying population
October 28 2016 by Nick Ferguson
-
Specialty carriers swoop for APAC’s emerging A&H opportunity
- November 13
The market is seeing an uptick in demand and rate correction in the region due to economic growth, demographic trends and inadequate public healthcare.
-
Price Forbes Singapore appoints Jennifer Gray as director of professional risks and healthcare
- November 4
Gray will focus on managing and expanding the broker's regional portfolio, leveraging her experience to drive growth through both domestic and international markets, and will be reporting to APAC CEO Philip Johnson.
-
Claims complexity, fraud and lack of quality data key challenges for regional health insurers
- October 30
Reinsurers' deep actuarial expertise and access to large data sets can help P&C carriers refine risk assessment and pricing strategies, says Peak Re’s Jasmine Miow.
-
Scor promotes Paula Bourke to CEO of life and health for ANZ
- October 16
Sydney-based Bourke was most recently the reinsurer's regional deputy CEO and global head of proposition and innovation, L&H.
-
BHSI | Managing non-Asian exposure in long-tail lines
While US-exposed business can look attractive to Asian carriers, managing the volatility around the long-term results and the ability to model those losses are crucial, say BHSI’s Marc Breuil and Marcus Portbury.
-
Sedgwick | To Handle CAT Claims Well, Multi-Step Preparation is Key
When it comes to risk, it’s not a matter of “if” it’s a matter of “when” an event will occur.
-
HSBC Asset Management | Is it time to relook at Asian currency bonds?
With diversification and performance high on investors’ agendas, it seems a good time for global portfolios to revive allocations in Asian local currency bonds – including Hong Kong dollar (HKD) bonds.
-
PineBridge Investments | Why Asian insurers are exploring private credit and CLOs
The recent rollout of risk-based capital regimes across Asia calls for a closer alignment between insurers’ assets and liabilities. We explore potential ways to maintain a healthy investment yield and robust returns on regulatory capital.
